Skip to Content
Contact DCTD
Show menu
Search this site
Last Updated: 05/23/2018

2018 American Society of Clinical Oncology (ASCO) Annual Meeting

Schedule of DCTD Presentations

DCTD-supported research will be presented at the ASCO Annual Meeting External Link in Chicago, IL from June 1-5, 2018 via the following four presentation categories:

Oral Presentations

Time Title Location
Friday, June 1
3:45 PM — 3:57 PM Molecular analysis for therapy choice (MATCH) arm W: Phase II study of AZD4547 in patients with tumors with aberrations in the FGFR pathway External Link S406
Saturday, June 2
8:00 AM — 8:12 AM Ado-trastuzumab emtansine (T-DM1) in patients (pts) with HER2 amplified (amp) tumors excluding breast and gastric/gastro-esophageal junction (GEJ) adenocarcinomas: Results from the National Cancer Institute (NCI) Molecular Analysis for Therapy Choice (MATCH) trial External Link Hall D1
8:12 AM — 8:24 AM Results from molecular analysis for therapy choice (MATCH) arm I: Taselisib for PIK3CA-mutated tumors External Link Hall D1
4:00 PM — 4:12 PM SPRINT: Phase II study of the MEK 1/2 inhibitor selumetinib (AZD6244, Arry-142886) in children with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN) External Link S504
Sunday, June 3
12:10 PM — 12:30 PM Rational Approach to Utilizing Genetic Information External Link
Elise Kohn, MD, Cancer Therapy Evaluation Program
S100bc
1:45 PM — 2:00 PM TAILORx: Phase III trial of chemoendocrine therapy versus endocrine therapy alone in hormone receptor-positive, HER2-negative, node-negative breast cancer and an intermediate prognosis 21-gene recurrence score External Link Hall B1
Monday, June 4
8:00 AM — 8:12 AM Phase III, randomized, double blind, placebo-controlled trial of sorafenib in desmoid tumors (Alliance A091105) External Link S100a
10:00 AM — 10:12 AM Durable tumor regression and overall survival (OS) in patients with advanced Merkel cell carcinoma (aMCC) receiving pembrolizumab as first-line therapy External Link Arie Crown Theater
5:05 PM — 5:25 PM Next-Generation Platform Trials: Innovation in trial design
Optimal source for molecular characterization

Mickey Williams, PhD, Frederick National Laboratory for Cancer Research
S100a
Tuesday, June 5
8:00 AM — 8:20 AM Coming Soon? New Treatments in Ovarian Cancer External Link
Charles Kunos, MD, PhD, Cancer Therapy Evaluation Program
S100a

Poster Presentations

Time Title Location
Saturday, June 2
8:00 AM — 11:30 AM A phase I NANT study of lenalidomide with ch14.18 and isotretinoin (RA) in patients with refractory/recurrent neuroblastoma (RR-NB) External Link Hall A
Abstract 10522
Poster #195
8:00 AM — 11:30 AM Pediatric preclinical testing consortium evaluation of the EZH2 inhibitor tazemetostat in orthotopic PDX models of pediatric brain tumors External Link Hall A
Abstract 10551
Poster #224
1:15 PM — 4:45 PM Combination of dabrafenib (DAB) and lapatinib (LAP) for the treatment of BRAF-mutant thyroid cancer External Link Hall A
Abstract 6087
Poster #75
1:15 PM — 4:45 PM Use of next-generation sequencing test to guide cancer treatment: Results from a survey of U.S. oncologists External Link Hall A
Abstract 6529
Poster #355
1:15 PM — 4:45 PM Prevalence of HIV, hepatitis B virus (HBV), and hepatitis C virus (HCV) among newly diagnosed cancer patients treated in academic and community oncology practices: SWOG S1204 External Link Hall A
Abstract 6600
Poster #425
Sunday, June 3
8:00 AM — 11:30 AM NCI 10066: A phase 1/2 study of olaparib in combination with ramucirumab in metastatic gastric and gastroesophageal junction (GEJ) adenocarcinoma External Link Hall A
Abstract TPS4137
Poster #323a
8:00 AM — 11:30 AM Targeting NFE2L2 mutations in advanced squamous cell lung cancers with the TORC1/2 inhibitor TAK228 External Link Hall A
Abstract 9098
Poster #421
Monday, June 4
8:00 AM — 11:30 AM Phase I study of recombinant interleukin-15 in combination with checkpoint inhibitors nivolumab and ipilimumab in subjects with refractory cancers External Link
Geraldine O’Sullivan Coyne, MD, PhD, Developmental Therapeutics Clinic
Hall A
Abstract TPS3128
Poster #328b
8:00 AM — 11:30 AM Phase I trial of z-endoxifen with estrogen receptor imaging in adults with advanced hormone receptor-positive solid tumors including desmoid and gynecologic tumors External Link
Naoko Takebe, MD, PhD, Developmental Therapeutics Clinic
Hall A
Abstract 2516
Poster #342
8:00 AM — 11:30 AM Adverse events (AEs) in early phase cancer clinical trials External Link
Grace Mishkin, MPH, Cancer Therapy Evaluation Program
Hall A
Abstract 2542
Poster #368
8:00 AM — 11:30 AM FACTS: Factors affecting combination trial success External Link Hall A
Abstract 2544
Poster #370
8:00 AM — 11:30 AM Phase I trial of the triplet M6620 (formerly VX970) + veliparib + cisplatin in patients with advanced solid tumors External Link
Geraldine O’Sullivan Coyne, MD, PhD, Developmental Therapeutics Clinic
Hall A Abstract 2549
Poster #375
8:00 AM — 11:30 AM BAX-BAK heterodimer as a pharmacodynamic biomarker of on-target drug action of MCl-1 inhibitors to evaluate in vivo effectiveness External Link
Apurva Srivastava, PhD, Frederick National Laboratory for Cancer Research
Hall A
Abstract 2582
Poster #408
8:00 AM — 11:30 AM Safety, tolerability, and antitumor activity of once-daily Wee-1 inhibitor AZD 1775 External Link
Naoko Takebe, MD, PhD, Developmental Therapeutics Clinic
Hall A
Abstract 2587
Poster #413
8:00 AM — 11:30 AM AMC 095 (AIDS Malignancy Consortium): A phase I study of ipilimumab (IPI) and nivolumab (NIVO) in advanced HIV associated solid tumors (ST) with expansion cohorts in HIV associated solid tumors and classical Hodgkin lymphoma (cHL) External Link Hall A
Abstract TPS2597
Poster #422b
8:00 AM — 11:30 AM A phase II trial of the DNA methyl transferase inhibitor, SGI-110 (guadecitabine), in children and adults with wild type GIST, pheochromocytoma and paraganglioma associated with succinate dehydrogenase deficiency and HLRCC-associated kidney cancer External Link Hall A
Abstract TPS2608
Poster #428a
1:15 PM — 4:45 PM Pregnancies during and following trastuzumab (T) and/or lapatinib (L) in patients (pts) with HER2-positive (HER2+) early breast cancer (EBG): Analysis from the NeoALTTO (BIG 1-06) and ALTTO (BIG 2-06) trials External Link Hall A
Abstract 10065
Poster #53
1:15 PM — 4:45 PM Impact of body mass index (BMI) and weight change after treatment in patients (pts) with HER2-positive (HER2+) early breast cancer (EBC): Secondary analysis of the ALTTO BIG 2-06 trial External Link Hall A
Abstract 10067
Poster #55
1:15 PM — 4:45 PM Assessment of the genomic stability and molecular landscape of patient-derived xenograft (PDX) models from NCI’s Patient-Derived Models Repository External Link
Biswajit Das, PhD, Frederick National Laboratory for Cancer Research
Hall A
Abstract 12023
Poster #136
1:15 PM — 4:45 PM A phase 2 biomarker trial of combination cediranib and olaparib in relapsed platinum (plat) sensitive and plat resistant ovarian cancer (ovca) External Link Hall A
Abstract 5519
Poster #246
1:15 PM — 4:45 PM Toxicity profile of patients with gynecological cancers (Gyne) enrolled phase I trials External Link Hall A
Abstract 5572
Poster #299
1:15 PM — 4:45 PM Immune checkpoint inhibitor (ICI) treatment in advanced melanoma (aMel) patients (pts) with renal or hepatic dysfunction (dysf): Real-world patient characteristics and outcomes External Link Hall A
Abstract 9569
Poster #396

Meet-the-Expert Presentations

NCI Exhibit Booth # 5041

Time Topic Presenter
Saturday, June 2
2:00 PM — 2:30 PM NCI’s National Clinical Trials Network Navigator: A Clinical Trials Specimen Resource Grace Mishkin, MPH
Cancer Therapy Evaluation Program
3:30 PM — 4:00 PM NCI National Clinical Laboratory Network Tracy Lively, PhD
Cancer Diagnosis Program
Sunday, June 3
10:30 AM — 11:00 AM The NCI Formulary: A Cancer Moonshot Initiative Jason Cristofaro, PhD, JD
Office of the Director
11:00 AM — 11:30 AM NCI’s Cancer Complementary and Alternative Medicine Programs and Activities Libin Jia, MD
Office of Cancer Complementary and Alternative Medicine
2:30 PM — 3:00 PM Precision Medicine Lyndsay Harris, MD
Cancer Diagnosis Program
3:30 PM — 4:00 PM NCI Precision Medicine Trials for Patients with Lung Cancer Shakun Malik, MD
Cancer Therapy Evaluation Program
Monday, June 4
11:00 AM — 11:30 AM Implementing NIH Clinical Trials Policies and Procedures: Key Changes to Know Lori Henderson, PhD
Cancer Imaging Program
2:00 PM — 2:30 PM Getting to IND: How NCI’s DTP Can Help Sundar Venkatachalam, PhD
Developmental Therapeutics Program
3:30 PM — 4:00 PM NCI Support for Targeted Radiopharmaceuticals Therapy Jacek Capala, PhD
Radiation Research Program

DCTD Staff Kiosk Schedule

NCI Exhibit Booth # 5041

Time Presenter
Saturday, June 2
1:00 PM — 3:00 PM Sumana Mukherjee Dey, PhD
Cancer Diagnosis Program
3:00 PM — 5:00 PM William Timmer, PhD
Cancer Therapy Evaluation Program
Sunday, June 3
11:00 AM — 1:00 PM Sundar Venkatachalam, PhD
Developmental Therapeutics Program
1:00 PM — 3:00 PM Nina Lukinova, PhD
Cancer Diagnosis Program
Monday, June 4
9:00 AM — 11:00 AM Sumana Mukherjee Dey, PhD
Cancer Diagnosis Program
11:00 AM — 1:00 PM Jacek Capala, PhD
Radiation Research Program
1:00 PM — 3:00 PM Magdalena Thurin, PhD
Cancer Diagnosis Program
3:00 PM — 5:00 PM Nina Lukinova, PhD
Cancer Diagnosis Program